| Overview |
| bs-6870R-FITC |
| ILP2 Polyclonal Antibody, FITC Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Rat |
| Human, Mouse, Chicken, Rabbit |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human ILP2 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 112401 |
| Cytoplasm, Nucleus |
| Baculoviral IAP repeat containing 8; Baculoviral IAP repeat containing protein 8; Baculoviral IAP repeat-containing protein 8; BIRC 8; BIRC8; BIRC8 protein; BIRC8_HUMAN; hILP 2; hILP2; IAP like protein 2; IAP-like protein 2; ILP 2; ILP-2; Inhibitor of apoptosis like protein 2; Inhibitor of apoptosis-like protein 2; Testis specic inhibitor of apoptosis; Testis-specic inhibitor of apoptosis. |
| Protects against apoptosis mediated by BAX.Apoptosis, or programmed cell death, is related to many diseases, such as cancer. Apoptosis is triggered by a variety of stimuli including members in the TNF family and prevented by the inhibitor of apoptosis (IAP) proteins. IAP proteins form a conserved gene family including IAP, XIAP/ILP-1/MIHA, and Livin/KIAP that bind to and inhibits specific proteases. A novel member in the IAP protein family was recently identified and designated ILP-2 for IAP-like protein-2 (1). ILP-2 has high homology to ILP-1, but is encoded by a distinct gene that is solely expressed in testis of tested normal human tissues (1). ILP-2, unlike ILP-1, has no inhibitory effect on Fas and TNF induced apoptosis, but potently inhibits apoptosis induced by overexpression of Bax or by coexpression of caspase-9 with Apaf-1. ILP-2 interacts with the processed caspase-9. These results suggest that ILP-2 is a novel IAP family member with restricted specificity for caspase-9. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |